Related Experiment Video

Updated: Sep 18, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

The development of novel and selective p56lck tyrosine kinase inhibitors

J L Bullington1, J C Cameron, J E Davis

  • 1R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.

Bioorganic & Medicinal Chemistry Letters
|January 5, 1999
PubMed

Insights

Indandiones are identified as potent inhibitors of p56lck, a critical tyrosine kinase in T-cell and NK cell function. This discovery offers a new therapeutic strategy for modulating immune cell responses.

Area of Science:

  • Immunology
  • Molecular Biology
  • Biochemistry

Background:

  • T-cell receptor (TCR) signaling initiates crucial immune responses.
  • p56lck (a tyrosine kinase) is vital for T-cell and NK cell proliferation and effector functions.
  • Dysregulation of p56lck activity is implicated in various immune disorders.

Purpose of the Study:

  • To identify novel inhibitors of the p56lck tyrosine kinase.
  • To explore the therapeutic potential of inhibiting p56lck in T-cell and NK cell-mediated processes.

Main Methods:

  • Biochemical assays to assess kinase inhibition.
  • Cell-based assays to evaluate T-cell and NK cell function.
  • Chemical screening to identify potent inhibitors.

Main Results:

  • Indandiones emerged as a potent and selective class of p56lck inhibitors.
  • Demonstrated significant inhibition of p56lck activity by indandiones.
  • Indandione treatment modulated T-cell and NK cell functions.

Conclusions:

  • Indandiones represent a promising new class of drugs for targeting p56lck.
  • Inhibiting p56lck with indandiones offers a potential therapeutic avenue for immune system modulation.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: